Latanoprost Upjohn Uk

Latanoprost, the active ingredient in Latanoprost Upjohn Uk, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure and is indicated for open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Upjohn Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost belongs to the prostaglandin analog class and is used to manage conditions that involve elevated intraocular pressure.

Open-angle glaucoma: reduces intraocular pressure to slow disease progression. Ocular hypertension: lowers pressure to prevent conversion to glaucoma. Elevated intraocular pressure (any cause): provides pressure reduction to protect optic nerve health.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash length and thickness. - Darkening of the iris color. - Transient blurred vision or foreign‑body sensation.

Serious or Rare Side Effects: - Severe ocular inflammation (uveitis or iritis). - Allergic reactions such as eyelid swelling or rash. - Paradoxical increase in intraocular pressure. - Corneal edema or endothelial dysfunction. - Vision loss due to optic nerve compromise.

Before initiating Latanoprost therapy, clinicians should consider several safety measures.

Monitor intraocular pressure: schedule regular tonometry assessments. Assess for ocular infections: avoid use if active conjunctivitis or keratitis is present. Avoid contact lens wear: discontinue lenses during treatment to reduce irritation. Caution in patients with asthma: prostaglandin analogues may exacerbate bronchospasm. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analogues: may increase local side‑effects. - Combination with systemic carbonic anhydrase inhibitors: additive pressure‑lowering effect may lead to hypotony.

Moderate Interactions (Monitor Closely): - Co‑administration with beta‑blocker eye drops: additive intraocular pressure reduction. - Use with alpha‑agonist eye drops: potential for excessive pressure lowering. - Systemic antihistamines: may reduce ocular absorption of the drug.